Search

Your search keyword '"Soliman, Hatem H."' showing total 42 results
Start Over Author "Soliman, Hatem H."
42 results on '"Soliman, Hatem H."'

1. Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases

Author

Khatri, Vaseem M., Mestres-Villanueva, Mariella A., Yarlagadda, Sreenija, Doniparthi, Ajay, Smith, David B., Nakashima, Justyn Y., Bryant, John M., Zhao, Dekuang, Upadhyay, Rituraj, Mills, Matthew N., Oliver, Daniel E., Yu, Hsiang-Hsuan Michael, Palmer, Joshua D., Williams, Nicole O., Mahtani, Reshma L., Ahluwalia, Manmeet S., Soliman, Hatem H., Han, Hyo S., Soyano, Aixa E., Kim, Youngchul, Kotecha, Rupesh, Beyer, Sasha J., and Ahmed, Kamran A.

Published
2024
Full Text
View/download PDF

3. The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs

Author

Mills, Matthew N., Potluri, Thrisha K., Kawahara, Yuki, Fahey, Matthew, Figura, Nicholas B., Soyano, Aixa E., Washington, Iman R., Diaz, Roberto, Oliver, Daniel E., Yu, Hsiang-Hsuan Michael, Etame, Arnold B., Vogelbaum, Michael A., Czerniecki, Brian J., Arrington, John A., Sahebjam, Solmaz, Forsyth, Peter A., Soliman, Hatem H., Han, Hyo S., and Ahmed, Kamran A.

Published
2022
Full Text
View/download PDF

5. Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study

Author

Ahmed, Kamran A., Kim, Youngchul, Arrington, John A., Kim, Sungjune, DeJesus, Michelle, Soyano, Aixa E., Armaghani, Avan J., Costa, Ricardo L.B., Khong, Hung T., Loftus, Loretta S., Rosa, Marilin, Caudell, Jimmy J., Diaz, Roberto, Robinson, Timothy J., Etame, Arnold B., Tran, Nam D., Sahebjam, Solmaz, Soliman, Hatem H., Czerniecki, Brian J., Forsyth, Peter A., Yu, H. Michael, and Han, Hyo S.

Published
2021
Full Text
View/download PDF

10. Figure S6. Serum Cytokines (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

11. Figure S2. Survival Outcomes By Tumor PD-L1 Levels (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Data from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

13. Figure S4 from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

14. Figure S5. Tumor Epithelial/Stromal Compartment CD8+ T-Cell Ratio in Tissue-Matched Metastatic Tumors (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

15. Figure S1. Study Design from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

16. Figure S3. Peripheral T-Cell Proliferation on Treatment (arm B parts 1 and 2) from Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., primary, Kim, Edward J., primary, George, Ben, primary, Kaylan, Aparna, primary, Chiorean, E. Gabriela, primary, Waterhouse, David M., primary, Guiterrez, Martin, primary, Parikh, Aparna, primary, Jain, Rishi, primary, Carrizosa, Daniel Ricardo, primary, Soliman, Hatem H., primary, Lila, Thomas, primary, Reiss, David J., primary, Pierce, Daniel W., primary, Bhore, Rafia, primary, Banerjee, Sibabrata, primary, Lyons, Larry, primary, Louis, Chrystal U., primary, Ong, Teng Jin, primary, and O'Dwyer, Peter J., primary

Published
2023
Full Text
View/download PDF

17. Abstract OT3-19-01: Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer

Author

Ahmed, Kamran A., primary, Kim, Youngchul, additional, Armaghani, Avan, additional, Arrington, John, additional, Costa, Ricardo, additional, Czerniecki, Brian J., additional, Diaz, Roberto, additional, Forsyth, Peter A., additional, Khong, Hung, additional, Lee, Kimberley, additional, Loftus, Loretta, additional, Rosa, Marilin, additional, Soliman, Hatem H., additional, Washington, Iman, additional, Soyano, Aixa, additional, and Han, Hyo S., additional

Published
2023
Full Text
View/download PDF

18. Abstract OT2-01-04: ELONA: An open-label, phase 1b-2 study of elacestrant, in combination with onapristone in patients with estrogen receptor-positive, progesterone receptor-positive, HER2-negative advanced or metastatic breast cancer

Author

Hamilton, Erika, primary, Pusztai, Lajos, additional, Soliman, Hatem H., additional, Hurvitz, Sara, additional, Grzegorzewski, Krzysztof, additional, Habboubi, Nassir, additional, Marreddy, Priya, additional, Sahmoud, Tarek, additional, and Ibrahim, Nuhad, additional

Published
2023
Full Text
View/download PDF

19. Abstract PD7-06: Characteristics of Long-Term Survival in Breast Cancer Brain Metastasis after Stereotactic Radiation

Author

Tang, Joseph D., primary, Mills, Matthew N., additional, Thawani, Chetna, additional, Oliver, Daniel E., additional, Soyano, Aixa, additional, Etame, Arnold, additional, Yu, Hsiang-Hsuan Michael, additional, Tran, Nam, additional, Vogelbaum, Michael A., additional, Forsyth, Peter A., additional, Czerniecki, Brian J., additional, Soliman, Hatem H., additional, Han, Hyo S., additional, and Ahmed, Kamran A., additional

Published
2023
Full Text
View/download PDF

20. Replicative Instability Drives Cancer Progression

Author

Morris, Benjamin B., primary, Smith, Jason P., additional, Zhang, Qi, additional, Jiang, Zhijie, additional, Hampton, Oliver A., additional, Churchman, Michelle L., additional, Arnold, Susanne M., additional, Owen, Dwight H., additional, Gray, Jhanelle E., additional, Dillon, Patrick M., additional, Soliman, Hatem H., additional, Stover, Daniel G., additional, Colman, Howard, additional, Chakravarti, Arnab, additional, Shain, Kenneth H., additional, Silva, Ariosto S., additional, Villano, John L., additional, Vogelbaum, Michael A., additional, Borges, Virginia F., additional, Akerley, Wallace L., additional, Gentzler, Ryan D., additional, Hall, Richard D., additional, Matsen, Cindy B., additional, Ulrich, C. M., additional, Post, Andrew R., additional, Nix, David A., additional, Singer, Eric A., additional, Larner, James M., additional, Stukenberg, Peter Todd, additional, Jones, David R., additional, and Mayo, Marty W., additional

Published
2022
Full Text
View/download PDF

21. Abstract OT2-09-01: Phase I/II study of stereotactic radiation and abemaciclib in the management of hormone receptor positive HER2 negative breast cancer brain metastases

Author

Ahmed, Kamran A., primary, Kim, Youngchul, additional, DeJesus, Michelle, additional, Beyer, Sasha J., additional, Williams, Nicole O., additional, Palmer, Joshua, additional, Woodhouse, Kristina D., additional, Murthy, Rashmi K., additional, Li, Jing, additional, Armaghani, Avan J., additional, Arrington, John A., additional, Costa, Ricardo L., additional, Czerniecki, Brian J., additional, Etame, Arnold B., additional, Forsyth, Peter A., additional, Khong, Hung T., additional, Oliver, Daniel E., additional, Rosa, Marilin, additional, Sahebjam, Solmaz, additional, Soliman, Hatem H., additional, Soyano, Aixa E., additional, Vogelbaum, Michael A., additional, Yu, Michael, additional, and Han, Hyo S., additional

Published
2022
Full Text
View/download PDF

22. Innovative Approaches in the Management of Metastatic Breast Cancer: Managed Care Considerations on the Evolving Role of Targeted Therapy.

Author

Soliman, Hatem H.

Subjects
THERAPEUTIC use of antineoplastic agents, MANAGED care programs, GENETIC mutation, METASTASIS, SIGNAL peptides, CONTINUING education units, SURVIVAL rate, CANCER patients, PROGRESSION-free survival, BREAST tumors, DISEASE management, ENZYME inhibitors, PALLIATIVE treatment
Abstract

Therapies targeting selected genetic mutations and protein expression have dramatically changed the treatment of metastatic breast cancer. Three of these, PARP, PI3K, and CDK 4/6 inhibitors have all been shown to improve progression-free survival and, for some of the agents, overall survival. [ABSTRACT FROM AUTHOR]

Published
2023

24. The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs

Author

Mills, Matthew N., primary, Potluri, Thrisha K., additional, Kawahara, Yuki, additional, Fahey, Matthew, additional, Figura, Nicholas B., additional, Soyano, Aixa E., additional, Washington, Iman R., additional, Diaz, Roberto, additional, Oliver, Daniel E., additional, Yu, Hsiang-Hsuan Michael, additional, Etame, Arnold B., additional, Vogelbaum, Michael A., additional, Czerniecki, Brian J., additional, Arrington, John A., additional, Sahebjam, Solmaz, additional, Forsyth, Peter A., additional, Soliman, Hatem H., additional, Han, Hyo S., additional, and Ahmed, Kamran A., additional

Published
2021
Full Text
View/download PDF

26. Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia

Author

Sun, James, primary, Zhong, Xiaojun, additional, Ma, Junjie, additional, Sun, Weihong, additional, Han, Hyo S., additional, Soliman, Hatem H., additional, Loftus, Loretta S., additional, Costa, Ricardo L. B., additional, Armaghani, Avan J., additional, Soyano‐Muller, Aixa E., additional, Czerniecki, Brian J., additional, Lee, M. Catherine, additional, Kiluk, John V., additional, Khakpour, Nazanin, additional, Hoover, Susan J., additional, Laronga, Christine, additional, and Khong, Hung T., additional

Published
2021
Full Text
View/download PDF

27. Abstract PS14-19: Characteristics of breast cancer brain metastases presentation by subtype and validation of the modified breast graded prognostic assessment

Author

Kawahara, Yuki, primary, Fahey, Matthew, additional, Potluri, Thrisha K, additional, Mills, Matthew N, additional, Figura, Nicholas B, additional, Washington, Iman R, additional, Diaz, Roberto, additional, Robinson, Timothy J, additional, Yu, Hsiang-Hsuan M, additional, Etame, Arnold B, additional, Liu, James, additional, Vogelbaum, Michael A, additional, Czerniecki, Brian J, additional, Forsyth, Peter A, additional, Soliman, Hatem H, additional, Han, Hyo S, additional, and Ahmed, Kamran A, additional

Published
2021
Full Text
View/download PDF

28. Open-label, Phase I Study of Nivolumab Combined with nab-Paclitaxel Plus Gemcitabine in Advanced Pancreatic Cancer

Author

Wainberg, Zev A., primary, Hochster, Howard S., additional, Kim, Edward J., additional, George, Ben, additional, Kaylan, Aparna, additional, Chiorean, E. Gabriela, additional, Waterhouse, David M., additional, Guiterrez, Martin, additional, Parikh, Aparna, additional, Jain, Rishi, additional, Carrizosa, Daniel Ricardo, additional, Soliman, Hatem H., additional, Lila, Thomas, additional, Reiss, David J., additional, Pierce, Daniel W., additional, Bhore, Rafia, additional, Banerjee, Sibabrata, additional, Lyons, Larry, additional, Louis, Chrystal U., additional, Ong, Teng Jin, additional, and O'Dwyer, Peter J., additional

Published
2020
Full Text
View/download PDF

29. Abstract P3-09-15: A phase 1b study of PVX-410 (PVX) vaccine plus durvalumab (DUR) as adjuvant therapy in HLA-A2+ early stage triple negative breast cancer (eTNBC) to assess safety and immune response

Author

Isakoff, Steven J, primary, Adams, Sylvia, additional, Soliman, Hatem H, additional, Tung, Nadine, additional, Barry, William T, additional, Hu, Jiani, additional, Trippa, Lorenzo, additional, Deering, Rachel, additional, Parker, Joanne, additional, Park, Hannah, additional, Brachtel, Elena F, additional, Ellisen, Leif W, additional, Severgnini, Mariano, additional, Peterkin, Doris, additional, and Tolaney, Sara M, additional

Published
2020
Full Text
View/download PDF

30. Abstract OT3-10-01: Phase Ib study of stereotactic radiation and nivolumab in the management of metastatic breast cancer with brain metastases

Author

Ahmed, Kamran A, primary, Kim, Youngchul, additional, Armaghani, Avan J., additional, Arrington, John A., additional, Caudell, Jimmy J., additional, Costa, Ricardo L., additional, Czerniecki, Brian J., additional, Etame, Arnold B., additional, Forsyth, Peter A., additional, Khong, Hung T., additional, Kim, Sungjune, additional, Loftus, Loretta, additional, Robinson, Timothy J., additional, Rosa, Marilin, additional, Sahebjam, Solmaz, additional, Soliman, Hatem H., additional, Soyano, Aixa E., additional, Tran, Nam D., additional, Yu, H. Michael, additional, and Han, Hyo S., additional

Published
2020
Full Text
View/download PDF

31. nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors

Author

Soliman, Hatem H

Subjects
nab-paclitaxel, Review, immunotherapy, solid tumors, chemotherapy, checkpoint inhibitors
Abstract

Tumors recognized by the host immune system are associated with better survival. However, the immune system is often suppressed in patients with established tumor burden. Stimulating the immune system to detect and kill tumor cells has been a challenge in cancer therapy for some time. Recently, novel cancer immunotherapies, such as immune checkpoint inhibitors, monoclonal antibodies, and vaccine therapies, have emerged as promising therapeutic approaches for many solid tumors. However, for some tumors, immunotherapy alone has not provided significant benefits, and some may even be fully resistant to immunotherapy. It has been suggested that the immune system may require “priming” before an immunotherapy can elicit an immune response. Although chemotherapies are believed to be immunosuppressive, when given at the right dose and sequence these agents may provide this “priming” effect for the immune system. In addition to direct cytotoxic killing of tumor cells, standard chemotherapeutic agents can elicit immunogenicity through various mechanisms. This review highlights the general immunomodulatory properties of chemotherapy agents. It also provides a rationale for combined therapy with nab-paclitaxel and immune checkpoint inhibitors. Recent clinical trial data with these combination regimens in solid tumors are presented, along with a summary of ongoing trials.

Published
2016

32. Personalizing Radiation Treatment Delivery in the Management of Breast Cancer

Author

Ahmed, Kamran A., Grass, G. Daniel, Orman, Amber G., Liveringhouse, Casey, Montejo, Michael E., Soliman, Hatem H., Han, Heather S., Czerniecki, Brian J., Torres-Roca, Javier F., and Diaz, Roberto

Subjects
Article Subject
Abstract

Long-term data establishes the efficacy of radiotherapy in the adjuvant management of breast cancer. New dose and fractionation schemas have evolved and are available, each with unique risks and rewards. Current efforts are ongoing to tailor radiotherapy to the unique biology of breast cancer. In this review, we discuss our efforts to personalize radiotherapy dosing using genomic data and the implications for future clinical trials. We also explore immune mechanisms that may contribute to a tumor’s unique radiation sensitivity or resistance.

Published
2018
Full Text
View/download PDF

36. A phase I study of indoximod in patients with advanced malignancies

Author

Soliman, Hatem H., primary, Minton, Susan E., additional, Han, Hyo Sook, additional, Ismail-Khan, Roohi, additional, Neuger, Anthony, additional, Khambati, Fatema, additional, Noyes, David, additional, Lush, Richard, additional, Chiappori, Alberto A., additional, Roberts, John D., additional, Link, Charles, additional, Vahanian, Nicholas N., additional, Mautino, Mario, additional, Streicher, Howard, additional, Sullivan, Daniel M., additional, and Antonia, Scott J., additional

Published
2016
Full Text
View/download PDF

37. Single drug biomarker prediction for ER- breast cancer outcome from chemotherapy.

Author

Yong-Zi Chen, Youngchul Kim, Soliman, Hatem H., GuoGuang Ying, and Lee, Jae K.

Subjects
HORMONE receptor positive breast cancer, CANCER chemotherapy, BIOLOGICAL tags, TRIPLE-negative breast cancer, PREDICTION models, CANCER treatment
Abstract

ER-negative breast cancer includes most aggressive subtypes of breast cancer such as triple negative (TN) breast cancer. Excluded from hormonal and targeted therapies effectively used for other subtypes of breast cancer, standard chemotherapy is one of the primary treatment options for these patients. However, as ER-- patients have shown highly heterogeneous responses to different chemotherapies, it has been diffcult to select most benefcial chemotherapy treatments for them. In this study, we have simultaneously developed single drug biomarker models for four standard chemotherapy agents: paclitaxel (T), 5-fuorouracil (F), doxorubicin (A) and cyclophosphamide (C) to predict responses and survival of ER-- breast cancer patients treated with combination chemotherapies. We then fexibly combined these individual drug biomarkers for predicting patient outcomes of two independent cohorts of ER-- breast cancer patients who were treated with different drug combinations of neoadjuvant chemotherapy. These individual and combined drug biomarker models signifcantly predicted chemotherapy response for 197 ER-- patients in the Hatzis cohort (AUC = 0.637, P = 0.002) and 69 ER-- patients in the Hess cohort (AUC = 0.635, P = 0.056). The prediction was also signifcant for the TN subgroup of both cohorts (AUC = 0.60, 0.72, P = 0.043, 0.009). In survival analysis, our predicted responder patients showed signifcantly improved survival with a >17 months longer median PFS than the predicted non-responder patients for both ER-- and TN subgroups (log-rank test P-value = 0.018 and 0.044). This fexible prediction capability based on single drug biomarkers may allow us to even select new drug combinations most benefcial to individual patients with ER-- breast cancer. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

38. ATNT-22A PHASE 1 STUDY OF TPI 287 CONCURRENT WITH FRACTIONATED STEREOTACTIC RADIOTHERAPY (FSRT) IN TREATMENT OF BRAIN METASTASES FROM ADVANCED BREAST AND NON-SMALL CELL LUNG (NSCL) CANCER

Author

Sahebjam, Solmaz, primary, Tran, Nam D., additional, Yu, H. Michael, additional, Arrington, John, additional, Soliman, Hatem H., additional, Tanvetyanon, Tawee, additional, Chen, Dung-Tsa, additional, Cooksey, Jennifer, additional, Hayes, Michael, additional, Montejo, Michael E., additional, Rao, Nikhil G., additional, Farmer, George, additional, Forsyth, Peter A., additional, and Johnstone, Peter A., additional

Published
2015
Full Text
View/download PDF

40. nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors.

Author

Soliman, Hatem H.

Subjects
*PACLITAXEL, *IMMUNE system, *CANCER cells, *MONOCLONAL antibodies, *IMMUNOTHERAPY, *CANCER chemotherapy, *IMMUNOSUPPRESSION
Abstract

Tumors recognized by the host immune system are associated with better survival. However, the immune system is often suppressed in patients with established tumor burden. Stimulating the immune system to detect and kill tumor cells has been a challenge in cancer therapy for some time. Recently, novel cancer immunotherapies, such as immune checkpoint inhibitors, monoclonal antibodies, and vaccine therapies, have emerged as promising therapeutic approaches for many solid tumors. However, for some tumors, immunotherapy alone has not provided significant benefits, and some may even be fully resistant to immunotherapy. It has been suggested that the immune system may require "priming"before an immunotherapy can elicit an immune response. Although chemotherapies are believed to be immunosuppressive, when given at the right dose and sequence these agents may provide this "priming" effect for the immune system. In addition to direct cytotoxic killing of tumor cells, standard chemotherapeutic agents can elicit immunogenicity through various mechanisms. This review highlights the general immunomodulatory properties of chemotherapy agents. It also provides a rationale for combined therapy with nab-paclitaxel and immune checkpoint inhibitors. Recent clinical trial data with these combination regimens in solid tumors are presented, along with a summary of ongoing trials. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

41. A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

Author

Soliman, Hatem H., primary, Jackson, Erica, additional, Neuger, Tony, additional, Dees, E. Claire, additional, Harvey, R. Donald, additional, Han, Hyo, additional, Ismail-Khan, Roohi, additional, Minton, Susan, additional, Vahanian, Nicholas N., additional, Link, Charles, additional, Sullivan, Daniel M., additional, and Antonia, Scott, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results